JEADV: Effectiveness of Hh pathway inhibitor Vismodegib in the treatment of locally advanced basal cell carcinoma in clinical practice

Basal cell carcinoma (BCC) is a cancer of the head, face, neck, or back of the hands that often occurs in the sun, and it is more common in the elderly.

Studies have shown that basal cell carcinoma may be caused by abnormal activation of the Hedgehog (Hh) signaling pathway, resulting in uncontrolled proliferation of cells from multiple epidermal compartments.

Vismodegib, a small molecule inhibitor of the Hh signaling pathway, has been approved for the treatment of locally advanced (la) BCC patients or symptomatic metastatic (m) BCC patients who cannot be treated with surgery or radiotherapy .

This study is a non-interventional trial that aims to evaluate the effectiveness of Vismodegib in the treatment of laBCC in clinical daily practice in Germany, focusing on the duration of remission (DOR) and the safety and utilization of Vismodegib.

All eligible patients who received at least one dose of Vismodegib between August 02, 2013 and March 31, 2016 were included in this analysis.

Duration of relief

During September 2015 and March 2019, a total of 66 patients were observed in 26 medical centers in Germany.

In conclusion, the study demonstrated the efficacy and safety of Vismodegib for laBCC patients, and confirmed that the key test results can be transformed into transplantability in routine clinical practice.

Original source:

Gutzmer R, Schulze HJ, Hauschild A et al.